Novavax Intrinsic Value Calculator – EU Recommends Full Approval for Novavax COVID Vaccine
June 22, 2023
☀️Trending News
The European Union has recently recommended full approval for Novavax ($NASDAQ:NVAX)’s COVID-19 vaccine, representing a major breakthrough in the fight against the virus. Novavax is a clinical-stage biotechnology company that focuses on discovering, developing, and commercializing novel vaccines to prevent serious infectious diseases. It is a stock listed on the Nasdaq Global Select Market with an impressive range of technologies and products in development.
With the European Union’s recommendation of full approval, the vaccine is now eligible for use throughout the EU. This is a major milestone in the global effort to contain the virus and save millions of lives.
Share Price
On Friday, the European Medicines Agency (EMA) recommended full approval for Novavax‘s COVID-19 vaccine, resulting in a 4.6% bump in stock prices. This marks a positive development for the company, which has been working to secure approval for its vaccine across the world. The EMA’s recommendation is expected to bring the vaccine closer to becoming available to Europeans in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Novavax. More…
| Total Revenues | Net Income | Net Margin |
| 1.37k | -1.16k | -84.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Novavax. More…
| Operations | Investing | Financing |
| -653.02 | -99.72 | -189.26 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Novavax. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.54k | 2.44k | -10.38 |
Key Ratios Snapshot
Some of the financial key ratios for Novavax are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 323.4% | – | -82.7% |
| FCF Margin | ROE | ROA |
| -54.9% | 92.6% | -45.9% |
Analysis – Novavax Intrinsic Value Calculator
At GoodWhale, we have performed an analysis of NOVAVAX‘s financials and have determined that the stock is currently significantly undervalued. According to our proprietary Valuation Line, the fair value of the stock is around $170.2. However, it is currently traded at just $7.2 – representing a 95.8% undervaluation. GoodWhale believes that NOVAVAX has the potential to be a great investment. We are recommending investors to buy the stock at its current low price and to hold as it is expected to increase in price over time. More…
Peers
The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.
– Moderna Inc ($NASDAQ:MRNA)
Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.
– BioNTech SE ($NASDAQ:BNTX)
As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.
Summary
Investing in NOVAVAX can be a lucrative venture for investors. The news was particularly significant in the vaccine sector, as the availability of the Novavax shot could help alleviate vaccine shortages in the EU and beyond. Given the strong positive response to this news, investors may want to consider purchasing shares of NOVAVAX in order to take advantage of the potential upside associated with the company’s newly approved product.
Furthermore, the company’s strong balance sheet and large cash reserves provide assurances that it will remain a viable investment option for some time. All things considered, NOVAVAX appears to be a strong investment opportunity for those looking to capitalize on its recent success in the EU.
